For personal use only

ASX Announcement / Media Release

27 February 2020

Financial Report – Half-Year ended 31 December 2019

Half-Yearly Report – Appendix 4D

Sydney, Australia – 27 February 2020: OncoSil Medical Ltd (ASX: OSL) (**OncoSil** or the **Company**), a medical device company focused on localised treatments for patients with pancreatic and liver cancer, is pleased to report its financial results for the half year ended 31 December 2019 (the **Half-Year**) (the **Financial Report**) and its Appendix 4D. All financial results are in Australian dollars and are unaudited.

Regulatory and Operational Highlights

During the period, the Company progressed on its CE Mark submission for the OncoSil™ device as it entered the final phase of review by the British Standards Institution (BSI). Highlights in the six months included:

- Multiple meetings with BSI management to progress the CE Mark submission into final review phase
- The Clinical Oversight Committee (COC) closed out concerns with the external clinical and bio-statistical experts
- OncoSil presented its Post-Market Surveillance (PMS) Plan and Post-Market Clinical Follow-Up (PMCF) programme for the OncoSil™ device
- The US Food and Drug Administration (FDA) granted OncoSil a Humanitarian Use Designation (HUD) for both intrahepatic (ICC) and distal cholangiocarcinoma (dCCA)

OncoSil's CE Mark certification is in the final phase of internal peer review assessment as confirmed by BSI and is approaching final CE Marking decision.

The Company remains confident of a positive CE Mark recommendation and will provide the market with an update on developments with respect to the decision.

Financial Highlights

- Cash, cash equivalents and financial assets balance as at 31 December 2019 of $6.8M
- R&D tax incentive refund of $3.8M received (2018: $4.3M) during the half year period

Commenting on the activities during the period, OncoSil Chief Executive Officer Daniel Kenny said, "The first half of the financial year was focused on progressing our CE Mark submission and we have made positive progress on this front with BSI entering the final phase of review."

"At the same time, we advanced on the US regulatory front, having been granted Humanitarian Use Designation status by the FDA for the OncoSil device for both intrahepatic (ICC) and distal cholangiocarcinoma."

For personal use only

"In anticipation of a positive CE Mark decision, we also began laying the foundations to support commercialisation activities in the EU. This included meetings with key hospitals across the region, enhanced logistical arrangements in preparation for commercial shipment and development of a promotional campaign for Health Care Professionals to be commenced post CE Mark approval."

"Noting that all clinical, technical and statistically concerns previously raised by the Clinical Oversight Committee have been closed out since October 2019, we remain confident of a positive CE Mark approval for the OncoSil™ device. We will update the market on developments on this front."

-ENDS-

Authorisation & Additional Information

This announcement was authorised by the Board of Directors of OncoSil Limited

Company	Media
Mr Daniel Kenny CEO & Managing Director E: daniel.kenny@oncosil.com.au T: +61 2 9223 3344	**Arthur Chan** WE Communications E: arthurc@we-worldwide.com M: 0404 369 388

About OncoSil

OncoSil Medical is a medical device company seeking to advance radiation for cancer patients. OncoSil Medical's lead product, OncoSil™ is a targeted radioactive isotope (Phosphorus-32), implanted directly into a patient's pancreatic tumours via an endoscopic ultrasound.

Treatment with the OncoSil™ is intended to deliver more concentrated and localised beta radiation compared to external beam radiation. OncoSil Medical has conducted four clinical studies with encouraging results on tolerability, safety and efficacy. A CE Mark application to commercially sell OncoSil™ in the European Union (EU) is under review.

The U.S Food and Drug Administration granted an Investigational Device Exemption (IDE) in July 2016 with approval to conduct a clinical study of the OncoSil™ device. The aim of the study will be to collect safety and effectiveness data required to support a Premarket Approval (PMA) application.

An Investigational Device Exemption (IDE) has been granted by the United States Food and Drug Administration (FDA) to conduct a clinical study of the OncoSil™ device aimed at supporting a PMA approval. Pancreatic cancer is typically diagnosed at a later stage, when there is a poor prognosis for long-term survival. The World Cancer Research Fund estimated that in 2012, 338,000 people globally were diagnosed with pancreatic cancer. The prognosis for patients diagnosed with pancreatic cancer, regardless of stage, is generally poor; the relative five-year survival rate for all stages combined is approximately 5%. The estimated world- wide market opportunity for OncoSil™ in pancreatic cancer exceeds $1b.

Hepatocellular carcinoma (HCC) or liver cancer, is the 6th most common cancer in the world with 782,000 new cases diagnosed in 2012. While hepatocellular carcinoma can be treated by surgery or

transplantation, the majority of patients with HCC have disease which is too advanced for surgery and their survival ranges from a few months to two or more years. The value of the hepatocellular cancer market is expected to triple in size to $1.4b by 2019.

Forward Looking Statements

This document contains certain forward-looking statements, relating to OncoSil's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA and other authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. OncoSil Medical is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

For personal use only

OncoSil Medical Ltd
Appendix 4D
Half-year report

1. Company details

Name of entity:	OncoSil Medical Ltd
ABN:	89 113 824 141
Reporting period:	For the half-year ended 31 December 2019
Previous period:	For the half-year ended 31 December 2018

2. Results for announcement to the market

The Group has adopted Accounting Standard AASB 16 'Leases' for the half-year ended 31 December 2019 using the modified retrospective approach and as such the comparatives have not been restated.

				$
Other income and interest revenue	down	36.2%	to	1,237,202
Loss from ordinary activities after tax attributable to the owners of OncoSil Medical Ltd	down	34.0%	to	(3,400,492)
Loss for the half-year attributable to the owners of OncoSil Medical Ltd	down	34.0%	to	(3,400,492)

Dividends
There were no dividends paid, recommended or declared during the current financial period.

Comments
The loss for the Group after providing for income tax amounted to $3,400,492 (31 December 2018: $5,149,905).

Further information on the results is detailed in the 'Review of operations' section of the Directors' report which is part of the Interim Report.

AASB 16 'Leases' had no significant impact on the current period. The current loss before income tax expense was increased by $794. This included an increased depreciation expense of $61,342 and increased finance costs of $5,112, offset by a reduction in occupancy expenses (reclassification of lease expenses) of $65,660. As at 31 December 2019, net current assets were reduced by $124,073 (attributable to current lease liabilities) and net assets were reduced by $794 (attributable to right-of-use assets and lease liabilities).

3. Net tangible assets

	Reporting period Cents	Previous period Cents
Net tangible assets per ordinary security	1.13	2.14

4. Control gained over entities

Not applicable.

5. Loss of control over entities

Not applicable.

For personal use only

For personal use only

6. Dividend reinvestment plans

Not applicable.

7. Details of associates and joint venture entities

Not applicable.

8. Foreign entities

Details of origin of accounting standards used in compiling the report:

Not applicable.

9. Audit qualification or review

Details of audit/review dispute or qualification (if any):

The financial statements were subject to a review by the auditors and the review report is attached as part of the Interim Report.

10. Attachments

Details of attachments (if any):

The Interim Report of OncoSil Medical Ltd for the half-year ended 31 December 2019 is attached.

11. Signed

Signed _____ Date: 27 February 2020

Dr Chris Roberts
Non-Executive Chairman
Sydney

For personal use only

OncoSil Medical Ltd

ABN 89 113 824 141

Interim Report - 31 December 2019

OncoSil Medical Ltd
Directors' report
31 December 2019

For personal use only

The directors present their report, together with the financial statements, on the consolidated entity (referred to hereafter as the 'Group') consisting of OncoSil Medical Ltd (referred to hereafter as the 'Company' or 'parent entity') and the entities it controlled at the end of, or during, the half-year ended 31 December 2019.

Directors

The following persons were directors of OncoSil Medical Ltd during the whole of the financial half-year and up to the date of this report, unless otherwise stated:

Dr Chris Roberts - Non-Executive Chairman
Mr Daniel Kenny - Chief Executive Officer and Managing Director
Dr Roger Aston - Non-Executive Director
Dr Martin Cross - Non-Executive Director
Mr Michael Bassett - Non-Executive Director

Principal activities

The principal activities of the Group during the financial half-year focused on the development of its lead product candidate, the OncoSil™ localised radiation therapy for the treatment of pancreatic cancer.

Review of operations

The loss for the Group after providing for income tax amounted to $3,400,492 (31 December 2018: $5,149,905).

OncoSil Medical is an ASX-listed, clinical stage medical device company which has developed a breakthrough implantable radiation treatment for cancer patients. OncoSil's lead product, the OncoSil device, is a first-in-class brachytherapy device for the treatment of locally advanced pancreatic cancer utilising ultrasound-guided endoscopy.

During the six-month period, the Company's focus was on advancing its application for CE Marking for the OncoSil device in the European Union (EU). This included meetings with regulatory authorities and preparing the necessary post-market plans for presentation with the British Standards Institution (BSI). In addition to this, the Company also put foundations in place for its commercialisation strategy (in anticipation of a positive regulatory outcome) and progressed on its regulatory plan for the United States (US).

The key developments and highlights for the first half of the 2020 financial year are as follows:

- OncoSil met with BSI and its Clinical Oversight Committee (COC) on multiple occasions to progress the CE Mark certification review to its final phase. This included:
    - A comprehensive response to questions based on the results of the PanCO study. The response included updated and new clinical data, together with a Systematic Literature Review (SLR) on state-of-the-art chemotherapy (CT-only) and induction chemotherapy combined with consolidation chemoradiotherapy (ICT + CCRT).
    - A company presentation addressing all concerns and issues raised in the previous assessment by BSI and the COC. The presentation was presented at a meeting between OncoSil, BSI and the COC on 3 October in London.
    - Submission of an updated Clinical Evaluation Report (CER) as requested by the BSI which included the latest clinical data and analysis from the PanCo study.
    - Formally submission of the OncoSil device's Post-Market Surveillance (PMS) plan and Post-Market Clinical Follow-up (PMCF) programme. These plans outline the compliance regimen associated with the European roll out of the OncoSil device in the treatment of unresectable locally advanced pancreatic cancer.
- Positive progress on the US regulatory strategy – including the US Food and Drug Administration (FDA) granting OncoSil Medical a Humanitarian Use Designation (HUD) for both intrahepatic (ICC) and distal cholangiocarcinoma (dCCA).

The Company received $3.8M in cash refund under the R&D Tax Incentive Refund scheme in September 2019.

As at 31 December 2019, the Company had $6.8M in cash and cash equivalents and financial assets.

AASB 16 'Leases' had no significant impact on the current period. The current loss before income tax expense was increased by $794. This included an increased depreciation expense of $61,342 and increased finance costs of $5,112, offset by a reduction in occupancy expenses (reclassification of lease expenses) of $65,660. As at 31 December 2019, net current assets were reduced by $124,073 (attributable to current lease liabilities) and net assets were reduced by $794 (attributable to right-of-use assets and lease liabilities).

Significant changes in the state of affairs

There were no significant changes in the state of affairs of the Group during the financial half-year.

Auditor's independence declaration

A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out immediately after this directors' report.

This report is made in accordance with a resolution of directors, pursuant to section 306(3)(a) of the Corporations Act 2001.

On behalf of the directors

Dr Chris Roberts
Non-Executive Chairman

27 February 2020
Sydney

For personal use only

For personal use only

Crowe Sydney
ABN 97 895 683 573
Member of Crowe Global

Audit and Assurance Services

Level 15, 1 O'Connell Street
Sydney NSW 2000
Australia

Tel +61 2 9262 2155
Fax +61 2 9262 2190

www.crowe.com.au

27 February 2020

The Board of Directors
OncoSil Medical Ltd
Suite 402, Level 4
50 Berry Street,
NORTH SYDNEY NSW 2060

Dear Board Members

OncoSil Medical Ltd

In accordance with section 307C of the Corporations Act 2001, I am pleased to provide the following declaration of independence to the Directors of OncoSil Medical Ltd.

As lead audit partner for the review of the financial statements of OncoSil Medical Ltd for the half-year ended 31 December 2019, I declare that to the best of my knowledge and belief, that there have been no contraventions of:

(i) the auditor independence requirements of the Corporations Act 2001 in relation to the review; and
(ii) any applicable code of professional conduct in relation to the review.

Yours sincerely

Crowe Sydney

Crowe Sydney

John Haydon
Senior Partner

The title 'Partner' conveys that the person is a senior member within their respective division, and is among the group of persons who hold an equity interest (shareholder) in its parent entity, Findex Group Limited. The only professional service offering which is conducted by a partnership is the Crowe Australasia external audit division. All other professional services offered by Findex Group Limited are conducted by a privately owned organisation and/or its subsidiaries.

Findex (Aust) Pty Ltd, trading as Crowe Australasia is a member of Crowe Global, a Swiss verein. Each member firm of Crowe Global is a separate and independent legal entity. Findex (Aust) Pty Ltd and its affiliates are not responsible or liable for any acts or omissions of Crowe Global or any other member of Crowe Global. Crowe Global does not render any professional services and does not have an ownership or partnership interest in Findex (Aust) Pty Ltd. Services are provided by Crowe Sydney, an affiliate of Findex (Aust) Pty Ltd. Liability limited by a scheme approved under Professional Standards Legislation.

© 2019 Findex (Aust) Pty Ltd

OncoSil Medical Ltd
Contents
31 December 2019

For personal use only

OncoSil Medical Ltd
Statement of profit or loss and other comprehensive income
For the half-year ended 31 December 2019

For personal use only

	Note	Consolidated 31/12/2019 $	Consolidated 31/12/2018 $
Revenue			
Other income	4	1,181,615	1,832,975
Interest revenue calculated using the effective interest method		55,587	105,474
Expenses			
Employee benefits expense		(1,672,686)	(1,856,324)
Research and development expenses		(2,026,762)	(3,792,901)
Occupancy expenses		(56,088)	(82,103)
Consulting, finance and legal expenses		(537,379)	(616,837)
Share-based payments		22,263	(545,088)
Other administrative expenses		(361,930)	(195,101)
Finance costs	5	(5,112)	-
Loss before income tax expense		(3,400,492)	(5,149,905)
Income tax expense		-	-
Loss after income tax expense for the half-year attributable to the owners of OncoSil Medical Ltd		(3,400,492)	(5,149,905)
Other comprehensive income			
Items that may be reclassified subsequently to profit or loss			
Foreign currency translation		(22,745)	(43,862)
Other comprehensive income for the half-year, net of tax		(22,745)	(43,862)
Total comprehensive income for the half-year attributable to the owners of OncoSil Medical Ltd		(3,423,237)	(5,193,767)
		Cents	**Cents**
Basic earnings per share	11	(0.54)	(0.82)
Diluted earnings per share	11	(0.54)	(0.82)

The above statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes

OncoSil Medical Ltd
Statement of financial position
As at 31 December 2019

For personal use only

	Note	Consolidated 31/12/2019 $	Consolidated 30/06/2019 $
Assets			
Current assets			
Cash and cash equivalents		6,795,526	7,689,234
Trade and other receivables	6	1,218,187	3,819,044
Other assets		214,116	97,603
Total current assets		8,227,829	11,605,881
Non-current assets			
Plant and equipment		64,898	62,466
Right-of-use assets	7	143,131	-
Total non-current assets		208,029	62,466
Total assets		8,435,858	11,668,347
Liabilities			
Current liabilities			
Trade and other payables	8	674,894	767,608
Borrowings		85,641	-
Lease liabilities		124,073	-
Employee benefits		241,762	225,603
Total current liabilities		1,126,370	993,211
Non-current liabilities			
Lease liabilities		19,852	-
Total non-current liabilities		19,852	-
Total liabilities		1,146,222	993,211
Net assets		7,289,636	10,675,136
Equity			
Issued capital	9	52,317,231	52,257,231
Reserves		5,975,387	6,020,395
Accumulated losses		(51,002,982)	(47,602,490)
Total equity		7,289,636	10,675,136

The above statement of financial position should be read in conjunction with the accompanying notes

OncoSil Medical Ltd
Statement of changes in equity
For the half-year ended 31 December 2019

Consolidated	Issued capital $	Reserves $	Accumulated losses $	Total equity $
Balance at 1 July 2018	52,257,231	4,933,232	(39,035,759)	18,154,704
Loss after income tax expense for the half-year	-	-	(5,149,905)	(5,149,905)
Other comprehensive income for the half-year, net of tax	-	(43,862)	-	(43,862)
Total comprehensive income for the half-year	-	(43,862)	(5,149,905)	(5,193,767)
Transactions with owners in their capacity as owners:				
Share-based payments	-	545,088	-	545,088
Balance at 31 December 2018	52,257,231	5,434,458	(44,185,664)	13,506,025

Consolidated	Issued capital $	Reserves $	Accumulated losses $	Total equity $
Balance at 1 July 2019	52,257,231	6,020,395	(47,602,490)	10,675,136
Loss after income tax expense for the half-year	-	-	(3,400,492)	(3,400,492)
Other comprehensive income for the half-year, net of tax	-	(22,745)	-	(22,745)
Total comprehensive income for the half-year	-	(22,745)	(3,400,492)	(3,423,237)
Transactions with owners in their capacity as owners:				
Contributions of equity, net of transaction costs (note 9)	60,000	-	-	60,000
Share-based payments	-	(22,263)	-	(22,263)
Balance at 31 December 2019	52,317,231	5,975,387	(51,002,982)	7,289,636

The above statement of changes in equity should be read in conjunction with the accompanying notes

For personal use only

OncoSil Medical Ltd
Statement of cash flows
For the half-year ended 31 December 2019

For personal use only

	Note	Consolidated 31/12/2019 $	Consolidated 31/12/2018 $
Cash flows from operating activities			
Payments to suppliers and employees		(4,799,630)	(6,605,636)
Interest received		55,587	105,474
Research and development tax incentive		3,780,856	4,286,144
Net cash used in operating activities		(963,187)	(2,214,018)
Cash flows from investing activities			
Payments for property, plant and equipment		(15,614)	(14,828)
Net cash used in investing activities		(15,614)	(14,828)
Cash flows from financing activities			
Proceeds from issue of shares	9	60,000	-
Proceeds from borrowings		85,641	60,452
Repayment of lease liabilities		(60,548)	-
Net cash from financing activities		85,093	60,452
Net decrease in cash and cash equivalents		(893,708)	(2,168,394)
Cash and cash equivalents at the beginning of the financial half-year		7,689,234	15,205,216
Cash and cash equivalents at the end of the financial half-year		6,795,526	13,036,822

The above statement of cash flows should be read in conjunction with the accompanying notes

For personal use only

Note 1. General information

The financial statements cover OncoSil Medical Ltd as a Group consisting of OncoSil Medical Ltd (the 'Company' or 'parent entity') and the entities it controlled at the end of, or during, the half-year (the 'Group'). The financial statements are presented in Australian dollars, which is OncoSil Medical Ltd's functional and presentation currency.

OncoSil Medical Ltd is a listed public company limited by shares, incorporated and domiciled in Australia. Its registered office and principal place of business is:

Suite 402, Level 4
50 Berry Street
North Sydney NSW 2060

A description of the nature of the Group's operations and its principal activities are included in the directors' report, which is not part of the financial statements.

The financial statements were authorised for issue, in accordance with a resolution of directors, on 27 February 2020. The directors have the power to amend and reissue the financial statements.

Note 2. Significant accounting policies

These general purpose financial statements for the interim half-year reporting period ended 31 December 2019 have been prepared in accordance with Australian Accounting Standard AASB 134 'Interim Financial Reporting' and the Corporations Act 2001, as appropriate for for-profit oriented entities. Compliance with AASB 134 ensures compliance with International Financial Reporting Standard IAS 34 'Interim Financial Reporting'.

These general purpose financial statements do not include all the notes of the type normally included in annual financial statements. Accordingly, these financial statements are to be read in conjunction with the annual report for the year ended 30 June 2019 and any public announcements made by the Company during the interim reporting period in accordance with the continuous disclosure requirements of the Corporations Act 2001.

The principal accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period, unless otherwise stated.

New or amended Accounting Standards and Interpretations adopted

The Group has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period.

Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

The following Accounting Standards and Interpretations are most relevant to the Group:

AASB 16 Leases
The Group has adopted AASB 16 from 1 July 2019. The standard replaces AASB 117 'Leases' and for lessees eliminates the classifications of operating leases and finance leases. Except for short-term leases and leases of low-value assets, right-of-use assets and corresponding lease liabilities are recognised in the statement of financial position. Straight-line operating lease expense recognition is replaced with a depreciation charge for the right-of-use assets (included in operating costs) and an interest expense on the recognised lease liabilities (included in finance costs). In the earlier periods of the lease, the expenses associated with the lease under AASB 16 will be higher when compared to lease expenses under AASB 117. However, EBITDA (Earnings Before Interest, Tax, Depreciation and Amortisation) results improve as the operating expense is now replaced by interest expense and depreciation in profit or loss. For classification within the statement of cash flows, the interest portion is disclosed in operating activities and the principal portion of the lease payments are separately disclosed in financing activities. For lessor accounting, the standard does not substantially change how a lessor accounts for leases.

For personal use only

Note 2. Significant accounting policies (continued)

Impact of adoption
AASB 16 was adopted using the modified retrospective approach and as such the comparatives have not been restated. The impact of adoption on opening accumulated losses as at 1 July 2019 was nil as follows:

	1 July 2019 $
Operating lease commitments as at 1 July 2019 (AASB 117)	218,865
Operating lease commitments discount based on the weighted average incremental borrowing rate of 5% (AASB 16)	(14,392)
Right-of-use assets (AASB 16)	204,473
Lease liabilities - current (AASB 16)	(125,066)
Lease liabilities - non-current (AASB 16)	(79,407)
	(204,473)
Reduction in opening accumulated losses as at 1 July 2019	-

Practical expedients applied
In adopting AASB 16, the Group has used the following practical expedients permitted by the standard:
- accounted for operating leases with a remaining lease term of less than 12 months as at 1 July 2019 as short-term leases;
- excluded initial direct costs for the measurement of the right-of-use asset at the date of initial application; and
- used hindsight in determining the lease term where the contract contains options to extend or terminate the lease.

Right-of-use assets
A right-of-use asset is recognised at the commencement date of a lease. The right-of-use asset is measured at cost, which comprises the initial amount of the lease liability, adjusted for, as applicable, any lease payments made at or before the commencement date net of any lease incentives received, any initial direct costs incurred, and, except where included in the cost of inventories, an estimate of costs expected to be incurred for dismantling and removing the underlying asset, and restoring the site or asset.

Right-of-use assets are depreciated on a straight-line basis over the unexpired period of the lease or the estimated useful life of the asset, whichever is the shorter. Where the Group expects to obtain ownership of the leased asset at the end of the lease term, the depreciation is over its estimated useful life. Right-of use assets are subject to impairment or adjusted for any remeasurement of lease liabilities.

The Group has elected not to recognise a right-of-use asset and corresponding lease liability for short-term leases with terms of 12 months or less and leases of low-value assets. Lease payments on these assets are expensed to profit or loss as incurred.

Lease liabilities
A lease liability is recognised at the commencement date of a lease. The lease liability is initially recognised at the present value of the lease payments to be made over the term of the lease, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Group's incremental borrowing rate. Lease payments comprise of fixed payments less any lease incentives receivable, variable lease payments that depend on an index or a rate, amounts expected to be paid under residual value guarantees, exercise price of a purchase option when the exercise of the option is reasonably certain to occur, and any anticipated termination penalties. The variable lease payments that do not depend on an index or a rate are expensed in the period in which they are incurred.

Lease liabilities are measured at amortised cost using the effective interest method. The carrying amounts are remeasured if there is a change in the following: future lease payments arising from a change in an index or a rate used; residual guarantee; lease term; certainty of a purchase option and termination penalties. When a lease liability is remeasured, an adjustment is made to the corresponding right-of use asset, or to profit or loss if the carrying amount of the right-of-use asset is fully written down.

For personal use only

Note 3. Operating segments

Identification of reportable operating segments
The Group operates in one segment being the device development for new medical treatments. This is based on the internal reports that are reviewed and used by the Board of Directors (who are identified as the Chief Operating Decision Makers ('CODM')) in assessing performance and in determining the allocation of resources. There is no aggregation of operating segments.

The information reported to the CODM is on at least a monthly basis. The financial information presented in these financial statements is the same as that presented to the CODM.

Note 4. Other income

	Consolidated 31/12/2019 $	Consolidated 31/12/2018 $
Research and development tax incentive	1,168,746	1,815,778
Net gain on foreign exchange	12,544	16,999
Other	325	198
Other income	1,181,615	1,832,975

Note 5. Expenses

	Consolidated 31/12/2019 $	Consolidated 31/12/2018 $
Loss before income tax includes the following specific expenses:		
Depreciation		
Office equipment	13,182	19,089
Buildings right-of-use assets	61,342	-
Total depreciation	74,524	19,089
Finance costs		
Interest and finance charges paid/payable on lease liabilities	5,112	-

Note 6. Current assets - trade and other receivables

	Consolidated 31/12/2019 $	Consolidated 30/06/2019 $
Other receivables	49,441	38,188
Research and development tax incentive receivable	1,168,746	3,780,856
	1,218,187	3,819,044

For personal use only

Note 7. Non-current assets - right-of-use assets

	Consolidated 31/12/2019 $	Consolidated 30/06/2019 $
Buildings - right-of-use	204,473	-
Less: Accumulated depreciation	(61,342)	-
	143,131	-

The Group leases buildings for its offices under agreements of between 3 to 5 years with, in some cases, options to extend. The leases have various escalation clauses. On renewal, the terms of the leases are renegotiated.

Note 8. Current liabilities - trade and other payables

	Consolidated 31/12/2019 $	Consolidated 30/06/2019 $
Trade payables	641,946	363,987
Payroll liabilities	26,190	98,784
Other payables	6,758	304,837
	674,894	767,608

Note 9. Equity - issued capital

	Consolidated 31/12/2019 Shares	Consolidated 30/06/2019 Shares	Consolidated 31/12/2019 $	Consolidated 30/06/2019 $
Ordinary shares - fully paid	630,708,788	630,708,788	52,317,231	52,257,231

Movements in ordinary share capital

Details	Date	Shares	Issue price	$
Balance	1 July 2019	630,708,788		52,257,231
Loan funded employee options repaid	3 December 2019	-	$0.00	60,000
Balance	31 December 2019	630,708,788		52,317,231

Note 10. Contingent liabilities

There has been no change in the status of contingent liabilities since 30 June 2019.

The directors are not aware of any other commitments or contingencies as at 31 December 2019.

For personal use only

Note 11. Earnings per share

	Consolidated 31/12/2019 $	Consolidated 31/12/2018 $
Loss after income tax attributable to the owners of OncoSil Medical Ltd	(3,400,492)	(5,149,905)
	Number	**Number**
Weighted average number of ordinary shares used in calculating basic earnings per share	630,708,788	626,365,853
Weighted average number of ordinary shares used in calculating diluted earnings per share	630,708,788	626,365,853
	Cents	**Cents**
Basic earnings per share	(0.54)	(0.82)
Diluted earnings per share	(0.54)	(0.82)

69,088,462 shares on issue under the Employee Share Plan have not been included in the diluted earnings per share calculation as they are anti-dilutive.

Note 12. Events after the reporting period

No matter or circumstance has arisen since 31 December 2019 that has significantly affected, or may significantly affect the Group's operations, the results of those operations, or the Group's state of affairs in future financial years.

OncoSil Medical Ltd
Directors' declaration
31 December 2019

In the directors' opinion:

- the attached financial statements and notes comply with the Corporations Act 2001, Australian Accounting Standard AASB 134 'Interim Financial Reporting', the Corporations Regulations 2001 and other mandatory professional reporting requirements;
- the attached financial statements and notes give a true and fair view of the Group's financial position as at 31 December 2019 and of its performance for the financial half-year ended on that date; and
- there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable.

Signed in accordance with a resolution of directors made pursuant to section 303(5)(a) of the Corporations Act 2001.

On behalf of the directors

Dr Chris Roberts
Non-Executive Chairman

27 February 2020
Sydney

For personal use only

For personal use only

Crowe Sydney
ABN 97 895 683 573
Member of Crowe Global

Audit and Assurance Services

Level 15 1 O'Connell Street
Sydney NSW 2000
Australia

Tel +61 2 9262 2155
Fax +61 2 9262 2190

www.crowe.com.au

Independent Auditor's Review Report to the Members of OncoSil Medical Ltd

Report on the Half-Year Financial Report

We have reviewed the accompanying half-year financial report of OncoSil Medical Ltd ('the Consolidated Entity'), which comprises the statement of financial position as at 31 December 2019, the statement of profit or loss and other comprehensive income, statement of changes in equity and statement of cash flows for the half-year ended on that date, and notes to the financial statements, including a summary of significant accounting policies, and the directors' declaration.

Directors' Responsibility for the Half-Year Financial Report

The directors of the Consolidated Entity are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express a conclusion on the half-year financial report based on our review. We conducted our review in accordance with Auditing Standard on Review Engagements ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*, in order to state whether, on the basis of the procedures described, we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the *Corporations Act 2001* including: giving a true and fair view of the Consolidated Entity's financial position as at 31 December 2019 and its performance for the half-year ended on that date; and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*. As the auditor of the Consolidated Entity, ASRE 2410 requires that we comply with the ethical requirements relevant to the audit of the annual financial report.

The title 'Partner' conveys that the person is a senior member within their respective division, and is among the group of persons who hold an equity interest (shareholder) in its parent entity, Findex Group Limited. The only professional service offering which is conducted by a partnership is the Crowe Australasia external audit division. All other professional services offered by Findex Group Limited are conducted by a privately owned organisation and/or its subsidiaries.

Findex (Aust) Pty Ltd, trading as Crowe Australasia is a member of Crowe Global, a Swiss verein. Each member firm of Crowe Global is a separate and independent legal entity. Findex (Aust) Pty Ltd and its affiliates are not responsible or liable for any acts or omissions of Crowe Global or any other member of Crowe Global. Crowe Global does not render any professional services and does not have an ownership or partnership interest in Findex (Aust) Pty Ltd. Services are provided by Crowe Sydney, an affiliate of Findex (Aust) Pty Ltd. Liability limited by a scheme approved under Professional Standards Legislation.

© 2019 Findex (Aust) Pty Ltd.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Independence

In conducting our review, we have complied with the independence requirements of the *Corporations Act 2001*.

Conclusion

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the half-year financial report of the Consolidated Entity is not in accordance with the *Corporations Act 2001* including:

(a) giving a true and fair view of the Consolidated Entity's financial position as at 31 December 2019 and of its performance for the half-year ended on that date; and
(b) complying with Accounting Standard AASB 134 *Interim Financial Reporting* and *Corporations Regulations 2001*.

Crowe Sydney

John Haydon
Senior Partner

Dated this 27th day of February 2020

For personal use only

© 2019 Findex (Aust) Pty Ltd